Amarin Vascepa reduced major unwanted cardiovascular events with 25% in large scale REDUCE IT study – Amarin Corporation PLC (NASDAQ: AMRN)

The results from the 8.179 topic REDUCE-IT study that evaluated Amarins (NASDAQ: AMRN) Vascepa (icosapent ethyl) in statin-treated adults with elevated cardiovascular (CV) risk showed a significant therapeutic effect.

The data was presented at AHA Scientific Sessions in Chicago and published simultaneously in the New England Journal of Medicine .

REDUCE-IT assessed 4 g / day of Vascepa over a median of 4.9 years. It achieved the primary endpoint for a statistically valid 25% (hazard ratio = 0.75) reduction in a composite of cardiovascular death, non-lethal heart attack, nonfatal stroke, coronary revascularization and unstable angina requiring hospitalization compared to statin treatment alone.

Patients receiving Vascepa due to statin treatment experienced 31[ads1]% less risk of myocardial infarction, 35% less risk of acute / evolving revascularization (stent or bypass surgery), 20% less risk of CV death, 32% less risk of hospitalization for unstable angina and 28% less risk of stroke. The risk of total mortality (CV and non-CV) was reduced by 13%.

CV benefits were not found to be significantly influenced by triglyceride levels between 135 mg / dL and 499 mg / dL at baseline, the targeted patient population for the Company's planned supplementary marketing authorization in early premature 2019 [Vascepa is currently approved in the U.S. for patients with severe hypertriglyceridemia (at least 500 mg/dL)].

The company emphasizes low cost for Vascepa compared to alternatives, with a monthly copy of $ 9.99 or less and the cost of a 90-day supply for as little as $ 9, depending on the type of insurance coverage.

Management said it is expanding its US sales association to over 400 employees.

Previously, Amarin reports positive results from the REDUCE-IT study; shares up 307% premarket (September 24)